女性心脏手术中急性等容血液稀释的安全性与有效性:ANH试验二次分析
该研究为多中心随机ANH试验的事后二次分析,纳入405例择期心脏手术女性患者,比较急性等容血液稀释与常规治疗的疗效与安全性。结果显示ANH未减少异体红细胞输注,但增加术中低血压风险并延长ICU和住院时间。
要点
- 女性心脏手术患者中,ANH未显著降低异体红细胞输注率。
- ANH组术中低血压发生率更高,ICU和住院时间更长。
- 该探索性发现需专门针对女性设计的研究证实。
核心结论
- 在女性心脏手术患者中,急性等容血液稀释未减少异体红细胞输注,且与更频繁的术中低血压及更长的ICU和住院时间相关。
研究设计与样本
- 多中心随机ANH试验的事后二次分析,纳入405例女性患者,其中219例接受ANH,186例接受常规治疗。
主要发现
- 死亡率及其他术后并发症无显著差异。
关键数值与推荐
- ANH干预措施为抽取至少650 mL全血并以晶体液替代,体外循环后回输。
- 主要结局为指数住院期间至少发生1次异体浓缩红细胞输注。
临床怎么用
- 女性心脏手术患者选择ANH时应权衡其未减少输血但增加低血压和延长住院的风险。
- 需在专门针对女性患者设计的足够把握度研究中进一步验证这些探索性结果。
局限性
- 本研究为事后二次分析,样本量有限,结果属探索性,有待专门设计的女性研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Female patients undergoing cardiac surgery have a higher transfusion burden, yet they remain underrepresented in randomized clinical trials. Although the ANH trial showed no significant reduction in the proportion of patients receiving allogeneic blood transfusions with acute normovolemic hemodilution, evidence regarding its efficacy and safety specifically in female patients remains limited. OBJECTIVE: To evaluate the efficacy and safety of acute normovolemic hemodilution (ANH) compared with usual care in female patients undergoing elective cardiac surgery with cardiopulmonary bypass. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc secondary analysis of the multicenter, randomized ANH trial, which was conducted at 32 centers in 11 countries from April 2019 to December 2024. Of 2010 patients in the original ANH trial, 405 were women and were included in this analysis; 219 had been randomized to receive ANH and 186 to usual care. This secondary analysis was conducted from August 2025 to January 2026. INTERVENTION: Withdrawal of at least 650 mL whole blood with crystalloids replacement and reinfusion after cardiopulmonary bypass. MAIN OUTCOMES AND MEASURES: The primary outcome was the occurrence of at least 1 allogeneic packed red blood cell (pRBC) transfusion during the index hospitalization. Safety outcomes included intraoperative hypotension, intensive care unit (ICU) length of stay, hospital length of stay, mortality, and other perioperative complications. RESULTS: The median (IQR) age of the participants was 62 (54-69) years. The occurrence of allogeneic pRBC transfusion was similar in the ANH and usual care groups (38.8% vs 44.6%, respectively; relative risk [RR], 0.87; 95% CI, 0.69-1.10; P = .24). Intraoperative hypotension occurred more frequently with ANH (16.0% vs 4.8% in usual care; RR, 3.30; 95% CI, 1.62-6.74; P = .02). Patients receiving ANH also had longer ICU stays (mean difference, 21.13 hours; 95% CI, 1.89-40.38; P = .03) and hospital stays (mean difference, 1.92 days; 95% CI, 0.14-3.70; P = .04). No significant differences were observed in mortality or other postoperative complications. CONCLUSIONS AND RELEVANCE: In this post hoc secondary analysis of a randomized clinical trial, ANH was not associated with a reduction in allogeneic pRBC transfusion among women undergoing cardiac surgery and was associated with more frequent intraoperative hypotension and longer ICU and hospital stay. These exploratory findings warrant confirmation in adequately powered studies specifically designed to evaluate female patients undergoing cardiac surgery. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03913481.
引用
- Pruna A, Scandroglio AM, Lei C, et al. Safety and Efficacy of Acute Normovolemic Hemodilution in Female Patients: A Secondary Analysis of the ANH Trial. JAMA Surg. 2026. PMID: 42873487. doi:10.1001/jamasurg.2026.4786
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。